ES2171356A1 - Uso de combinaciones que comprenden antihistaminas no sedantes y farmacos alfa-adrenergicos para el tratamiento topico de rinitis/conjuntivitis y sintomas de catarro, tipo catarro y/o gripe. - Google Patents

Uso de combinaciones que comprenden antihistaminas no sedantes y farmacos alfa-adrenergicos para el tratamiento topico de rinitis/conjuntivitis y sintomas de catarro, tipo catarro y/o gripe.

Info

Publication number
ES2171356A1
ES2171356A1 ES200050020A ES200050020A ES2171356A1 ES 2171356 A1 ES2171356 A1 ES 2171356A1 ES 200050020 A ES200050020 A ES 200050020A ES 200050020 A ES200050020 A ES 200050020A ES 2171356 A1 ES2171356 A1 ES 2171356A1
Authority
ES
Spain
Prior art keywords
cold
conjunctivitis
alpha
rhinitis
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200050020A
Other languages
English (en)
Other versions
ES2171356B2 (es
Inventor
Crespo Maria Del Carmen Diez
Roberto Mainardi
Istvan Szelenyi
Reinhard Muckenschnabel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda Pharma GmbH and Co KG
Original Assignee
Viatris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris GmbH and Co KG filed Critical Viatris GmbH and Co KG
Publication of ES2171356A1 publication Critical patent/ES2171356A1/es
Application granted granted Critical
Publication of ES2171356B2 publication Critical patent/ES2171356B2/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se reivindica una combinación farmacéutica, aplicable por vía tópica, que contiene una antihistamina no sedante en combinación con un agonista-alfa-adrenérgico y, opcionalmente, vehículos convencionales fisológicamente aceptables, agentes diluyentes y sustancias auxiliares para la profilaxis y el tratamiento de rinitis alérgica y/o vasomotora, conjuntivitis, síntomas de catarro, tipo catarro y/o gripe.
ES200050020A 1997-09-22 1998-09-11 Uso de combinaciones que comprenden azelastina y farmacos alfa-adrenergicos para el tratamiento topico de rinitis/conjuntivitis y sintomas de catarro, tipo catarro y/o gripe. Expired - Fee Related ES2171356B2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97116494 1997-09-22
EP97116494A EP0903151A1 (en) 1997-09-22 1997-09-22 Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms

Publications (2)

Publication Number Publication Date
ES2171356A1 true ES2171356A1 (es) 2002-09-01
ES2171356B2 ES2171356B2 (es) 2004-05-01

Family

ID=8227389

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200050020A Expired - Fee Related ES2171356B2 (es) 1997-09-22 1998-09-11 Uso de combinaciones que comprenden azelastina y farmacos alfa-adrenergicos para el tratamiento topico de rinitis/conjuntivitis y sintomas de catarro, tipo catarro y/o gripe.

Country Status (12)

Country Link
US (1) US20020037297A1 (es)
EP (1) EP0903151A1 (es)
JP (1) JP2001517639A (es)
AU (1) AU9540098A (es)
BR (1) BR9812361A (es)
CA (1) CA2304162A1 (es)
DE (1) DE19882573T1 (es)
ES (1) ES2171356B2 (es)
NO (1) NO20001459D0 (es)
PL (1) PL339541A1 (es)
WO (1) WO1999015203A1 (es)
ZA (1) ZA988638B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
EP1276502A1 (en) * 2000-04-14 2003-01-22 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
SK2805U (sk) * 2000-10-05 2001-03-12 Unimed Pharma Spol Sro Očná instilácia s dekongescentným účinkom
PE20020324A1 (es) * 2000-10-06 2002-06-18 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina
US20020094345A1 (en) 2000-10-06 2002-07-18 Sara Abelaira Pharmaceutical compositions containing epinastine and pseudoephedrine
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
EP1327463A1 (de) * 2002-01-04 2003-07-16 Oramon Arzneimittel GmbH Gel enthaltend Cetirizin und Loratadin zur topischen Anwendung
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
RU2005101331A (ru) * 2002-06-20 2006-01-20 Новартис Консьюмер Хелс С.А. (Ch) Назальная композиция, включающая мукополисахарид и пропиленгликоль
CN101327325A (zh) * 2002-07-30 2008-12-24 奥默罗斯公司 眼科冲洗液及方法
CA2495830C (en) * 2002-08-30 2012-08-21 Altana Pharma Ag The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US7714011B2 (en) * 2002-09-13 2010-05-11 Zicam, Llc Compositions to reduce congestion and methods for application thereof to the nasal membrane
US20040198828A1 (en) * 2003-01-17 2004-10-07 Abelson Mark B. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
JP2007039473A (ja) * 2003-02-19 2007-02-15 Rohto Pharmaceut Co Ltd 医薬組成物
JP2010241834A (ja) * 2003-02-19 2010-10-28 Rohto Pharmaceut Co Ltd 医薬組成物
JP2005330245A (ja) * 2004-05-21 2005-12-02 Kowa Co 鼻炎用薬
DE102004049008A1 (de) * 2004-10-05 2006-04-06 Merck Patent Gmbh Neue Verwendung für α-Sympathomimetika mit 2-Imidazolinstruktur
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP5607291B2 (ja) * 2004-11-24 2014-10-15 メダ ファーマシューティカルズ インコーポレイテッド アゼラスチンを含む組成物およびその使用方法
US7247623B2 (en) * 2005-08-19 2007-07-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with non-drying antihistamines
US20090136598A1 (en) * 2006-04-26 2009-05-28 Aciex, Inc. Compositions for the Treatment and Prevention of Eyelid Swelling
CA2650592A1 (en) * 2006-04-26 2007-11-08 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
US7378082B1 (en) 2007-11-05 2008-05-27 Inspire Pharmaceuticals, Inc. Method for treating allergic rhinitis without adverse effects
JP2008285474A (ja) * 2007-04-17 2008-11-27 Daiichi Sankyo Healthcare Co Ltd 抗アデノウイルス剤を含有する医薬組成物
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20150119401A1 (en) * 2008-08-01 2015-04-30 Eye Therapies, Llc Compositions and Methods for the Treatment of Nasal Conditions
HRP20141047T1 (hr) * 2008-08-01 2015-01-02 Eye Therapies Llc Pripravci za sužavanje krvnih žila i metode njihove uporabe
US20120156244A1 (en) * 2008-08-01 2012-06-21 Alpha Synergy Development Inc. Nasal Compositions and Uses Thereof
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US20110257188A1 (en) * 2008-08-01 2011-10-20 Gerald Horn Compositions and methods for the treatment of nasal conditions
EP2408453B1 (en) * 2009-03-17 2022-01-05 Nicox Ophthalmics, Inc. Ophthalmic formulations of cetirizine and methods of use
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
JP5752578B2 (ja) * 2011-12-09 2015-07-22 ジェイ−メド ファーマシューティカルズ，インコーポレーティッド 鼻炎治療のための単一投与抗ヒスタミン薬／鬱血除去薬製剤
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016068975A1 (en) * 2014-10-31 2016-05-06 Avon Products, Inc. Topical compositions and methods of use thereof
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
DE102016125378A1 (de) * 2016-12-22 2018-06-28 Werner Schmidt Zusammensetzung zur Behandlung von Erkältungskrankheiten
WO2018203424A1 (ja) * 2017-05-01 2018-11-08 参天製薬株式会社 点眼剤
RU2744097C2 (ru) * 2018-02-28 2021-03-02 Акционерное Общество "Вертекс" Комбинированное противоаллергическое лекарственное средство для назального применения

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822349A (en) * 1969-06-02 1974-07-02 C Kosti Vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue
JPH07188002A (ja) * 1993-12-27 1995-07-25 Taisho Pharmaceut Co Ltd 鼻炎治療用組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822349A (en) * 1969-06-02 1974-07-02 C Kosti Vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue
JPH07188002A (ja) * 1993-12-27 1995-07-25 Taisho Pharmaceut Co Ltd 鼻炎治療用組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ABELSON, M.B. et al.: "Effects of vasocon-A in the allergen challenge model of acute allergic conjunctivitis". Arch. ophtalmol., 1990, Vol. 108, no 4, paginas 520-524. Resumen. *
LANIER, B.Q. et al.: "A double-masked comparison of ocular decongestants as therapy for allergic conjunctivitis". Annals of allergy, 1983, Vol. 50, no 3, paginas 174-177. Paginas 174; pagina 175, tabla 1. *
LOZEWICZ, S. et al.: "Allergen-induced changes in the nasal mucous membrane in seasonal allergic rhinitis: Effect of nedocromil Sodium". Journal of allergic and clinical immunology, 1990, Vol. 85, no 1 (1), paginas 125-131. Pagina 126, columna 2, lineas 47-51. *
WERTHEIMER, R. et al.: "Antazolin/tetryzolinhaltige augentropfen im Vergleich zu levocabastinhaltigen augentropfen bei akuter allergischer konjunktivitis". Klin. Monatsbl Augenheilkol, 1997, Vol. 210, no 2, paginas 93-96. Resumen; pagina 94, tabla 2. *

Also Published As

Publication number Publication date
BR9812361A (pt) 2000-09-19
DE19882573T1 (de) 2000-10-26
AU9540098A (en) 1999-04-12
JP2001517639A (ja) 2001-10-09
ZA988638B (en) 1999-03-23
PL339541A1 (en) 2000-12-18
US20020037297A1 (en) 2002-03-28
ES2171356B2 (es) 2004-05-01
EP0903151A1 (en) 1999-03-24
WO1999015203A1 (en) 1999-04-01
CA2304162A1 (en) 1999-04-01
NO20001459L (no) 2000-03-21
NO20001459D0 (no) 2000-03-21

Similar Documents

Publication Publication Date Title
ES2171356A1 (es) Uso de combinaciones que comprenden antihistaminas no sedantes y farmacos alfa-adrenergicos para el tratamiento topico de rinitis/conjuntivitis y sintomas de catarro, tipo catarro y/o gripe.
PL370536A1 (en) Compositions for treatment of common cold
GB9917406D0 (en) Compounds
GB0118238D0 (en) Medicaments
GB0112836D0 (en) Medicaments
NO2013017I1 (no) (a)dekstrometorfan eller et farmasøytisk akseptabelt salt, en forløper eller derivat, for eksempel ekstrometorfanhydrobromid og spesielt dekstrometorfanhydrobromid monohydrat; og (b) quinidin eller etfarmasøytisk akseptabelt salt, en forløper eller derivat derav, for eksempel quinidin og spesielt quinidinsulfat dihydrat
AR092919A2 (es) Composicion farmaceutica liquida
WO2002089791A3 (de) Behandlung der akne mit lipoxygenase inhibitoren
NO20022334D0 (no) Ny sammensetning og anvendelse
GB0031088D0 (en) Medicaments
BRPI0009719B8 (pt) processo de tratamento
CA2474373A1 (en) N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substituent on the methyl useful as bradykinin antagonists
EE200300371A (et) Peroraalselt ja paikselt manustatavad farmatseutilised kopmositsioonid
WO2003065789A3 (en) N-biphenylmethyl aminocycloalkanecarboxamide derivatives
CO5031291A1 (es) Composicion farmaceutica
CA2427814A1 (en) A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
EE05211B1 (et) Saredutandi ja selle farmatseutiliselt vastuv?etavate soolade kasutamine meeleoluh„irete, kohanemish„irete v?i segatpi „rev-depressiivsete h„irete raviks v?i v„ltimiseks kasulike ravimite valmistamiseks
SE9903995D0 (sv) New combination
NO20054216L (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
NO20005147D0 (no) FremgangsmÕter og sammensetninger som benytter terfenadinmetabolitter i kombinasjon med leukotrienhemmere
BR0009289A (pt) Uso de inibidores da vasopeptidase para tratar angina pectoris
DK1239861T3 (da) Kombinationaf cyamemazin og et atypisk neuroleptikum
AU7393201A (en) Drug combination for the treatment of headache comprising a non-steroidal anti-inflammatory drug
NO20055767L (no) Farmasoytisk preparat for prevensjon og terapi av nikotinavhengighet hos et pattedyr
WO2002067938A3 (en) Treating or reducing the risk of cardiovascular disease

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020901

Kind code of ref document: A1

Effective date: 20020901

FG2A Definitive protection

Ref document number: 2171356B2

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20211118